Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis
- PMID: 33974984
- DOI: 10.1016/j.wneu.2021.04.138
Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis
Abstract
Background: Histologic grade has important implications for the management in meningioma. It is important to understand the risk of high-grade meningioma (grades II and III). In this article, we systematically reviewed the histologic grade of meningioma depending on the location and sex and its relationship with recurrence.
Methods: The PubMed and Embase databases were systematically searched until February 4, 2020. We included studies that were not restricted to specific anatomic locations, histologic grade, or the sizes of the tumors. The proportion of high-grade meningiomas depending on the location and sex and the odds ratio (OR) of recurrence were pooled using a random-effects model.
Results: Outcome data were analyzed for 20,336 tumors from 34 studies. We found different proportions of high-grade meningiomas in the brain (12.8%) (95% confidence interval [CI], 10.5%-15.1%) versus the spine (2.4%) (95% CI, 1.0%-3.7%) (P < 0.01). Skull base meningiomas (8.7%) (95% CI, 5.8%-11.6%) had a lower proportion of high-grade meningiomas than non-skull base meningiomas (16.5%) (95% CI, 11.9%-21.1%) (P < 0.01). In addition, high-grade meningiomas were more likely to occur in male patients (18.0%) (95% CI, 10.1%-25.9%) than female patients (7.0%) (95% CI, 3.5%-10.6%) (P = 0.01). Higher rates of recurrence (OR = 13.83) were confirmed for high-grade meningiomas than grade I meningiomas (95% CI, 4.10-46.65) (P < 0.01).
Conclusions: This meta-analysis found that intracranial, nonskull base, and male sex are risk factors for high-grade meningioma, and high-grade meningioma had a much higher recurrence rate as compared with grade I meningioma.
Keywords: High-grade meningioma; Meta-analysis; Recurrence; Risk factor.
Copyright © 2021. Published by Elsevier Inc.
Similar articles
-
A systematic review and individual participant data meta-analysis of gonadal steroid hormone receptors in meningioma.J Neurosurg. 2023 May 26;139(6):1638-1647. doi: 10.3171/2023.3.JNS221838. Print 2023 Dec 1. J Neurosurg. 2023. PMID: 37243565 Free PMC article.
-
WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma.Acta Neurochir (Wien). 2019 Dec;161(12):2553-2561. doi: 10.1007/s00701-019-04084-z. Epub 2019 Oct 21. Acta Neurochir (Wien). 2019. PMID: 31637512
-
Is location more determining than WHO grade for long-term clinical outcome in patients with meningioma in the first two decades of life?Wien Klin Wochenschr. 2025 Jan;137(1-2):21-30. doi: 10.1007/s00508-024-02382-w. Epub 2024 May 31. Wien Klin Wochenschr. 2025. PMID: 38819451 Free PMC article.
-
Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?J Neurooncol. 2018 Apr;137(2):331-336. doi: 10.1007/s11060-017-2721-4. Epub 2017 Dec 21. J Neurooncol. 2018. PMID: 29270884
-
Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases.Acta Neurochir (Wien). 2013 Mar;155(3):407-13. doi: 10.1007/s00701-012-1611-y. Epub 2013 Jan 15. Acta Neurochir (Wien). 2013. PMID: 23318687 Review.
Cited by
-
Prognosis and histology of sporadic synchronous and metachronous meningiomas and comparative analyses with singular lesions.Neurosurg Rev. 2023 Feb 13;46(1):55. doi: 10.1007/s10143-023-01958-w. Neurosurg Rev. 2023. PMID: 36781550 Free PMC article.
-
Impact of 2021 World Health Organization Grading, Peritumoral Edema, and Radiotherapy on the Recurrence of a Grossly Resected Intracranial Meningiomas: A Ten-Year Follow-Up Study.World J Oncol. 2025 Feb;16(1):95-103. doi: 10.14740/wjon1999. Epub 2025 Jan 7. World J Oncol. 2025. PMID: 39850529 Free PMC article.
-
Intelligent noninvasive meningioma grading with a fully automatic segmentation using interpretable multiparametric deep learning.Eur Radiol. 2023 Sep;33(9):6124-6133. doi: 10.1007/s00330-023-09590-4. Epub 2023 Apr 13. Eur Radiol. 2023. PMID: 37052658
-
Clinical, molecular, and genetic features of spinal meningiomas.Neurooncol Adv. 2024 Aug 31;6(Suppl 3):iii73-iii82. doi: 10.1093/noajnl/vdae123. eCollection 2024 Oct. Neurooncol Adv. 2024. PMID: 39430393 Free PMC article. Review.
-
Introduction: Ongoing clinical challenges in the management of meningiomas and future directions.Neurooncol Adv. 2023 Jun 3;5(Suppl 1):i1-i4. doi: 10.1093/noajnl/vdad030. eCollection 2023 May. Neurooncol Adv. 2023. PMID: 37287579 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources